Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of being satiated, with the biopharma paying $25 million upfront to Arrowhead ...

Bill Sibold, Madrigal Pharma's chief executive. Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer, hoping to build on its first-mover ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company's flagship drug is ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Alphabet briefly surpassed Nvidia by market cap in after-hours trading this week. Wall Street is increasingly bullish on the company's ability to win in AI at various levels, whether it's in the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Leo Madrigal packs more than 30 years of kitchen experience into his enchiladas. For his green chile enchiladas, the Mexico City-born chef gives pork the slow-and-low barbacoa treatment. The pork is ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and ...

Khadija Khartit is a strategy, investment, and funding expert, and an educator of fintech and strategic finance in top universities. She has been an investor, entrepreneur, and advisor for more than ...

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and ...

Madrigal Pharmaceuticals has licensed from Arrowhead Pharmaceuticals an RNA interference candidate that targets a genetic mutation present in around 30% of patients with MASH. Madrigal Pharmaceuticals ...